Biovica International AB (9II)
Market Open
12 Aug, 06:04
XFRA XFRA Primary XMUN €
0. 04
-0
-5.9701%
€
16.89M Market Cap
- P/E Ratio
- Div Yield
2,700 Volume
- Eps
€ 0.04
Previous Close Want to track 9II and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
9II trading today lower at €0.04, a decrease of -5.9701% from yesterday's close, completing a monthly increase of 1,474.9999% or €0.04. Over the past 12 months, 9II stock gained 844.9999%.
9II is not paying dividends to its shareholders.
The last earnings report, released on Mar 18, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Biovica International AB (9II) FAQ
What is the stock price today?
The current price is €0.04.
On which exchange is it traded?
Biovica International AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 9II.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 16.89M.
Has Biovica International AB ever had a stock split?
No, there has never been a stock split.
Biovica International AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Anders Rylander CEO | XFRA Exchange | SE0008613731 ISIN |
| Sweden Country | 27 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Biovica International AB (publ) is a biotech enterprise based in Uppsala, Sweden, dedicated to the development and commercialization of innovative blood-based biomarker assays designed to improve the monitoring and prediction of cancer therapy outcomes in the United States. With a strong R&D foundation established since its inception in 2008, Biovica places a significant emphasis on breast cancer, striving to address the urgent needs of cancer institutes, pharmaceutical entities, and collaborative groups in the oncology sector.
Products and Services
- DiviTum TKa - A groundbreaking blood-based biomarker assay, DiviTum TKa represents the pinnacle of Biovica's commitment to advancing cancer treatment monitoring. It precisely measures thymidine kinase activity, a potent indicator of cell proliferation, thereby offering a reliable method for assessing the efficacy of cancer therapies. By facilitating a deeper understanding of treatment response, this assay enables healthcare providers to make more informed decisions, tailoring interventions to accelerate patient recovery and improve outcomes.
Contact Information
Address: Dag HammarskjOelds vAeg 54B
Phone: 46 1 84 44 48 30
Website: https://www.biovica.com
